STAT Plus: After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors By MATTHEW HERPER

https://www.statnews.com/2020/02/21/after-21-year-journey-esperion-to-test-market-for-a-cholesterol-pill-that-is-less-expensive-than-some-competitors/?utm_source=STAT+Newsletters&utm_campaign=485c52ce01-Daily_Recap&utm_medium=email&utm_term=0_8cab1d7961-485c52ce01-149692869

STAT Plus: After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

By MATTHEW HERPER

APSTOCK

The approval of Nexletol will allow Esperion to test whether price is the biggest barrier to new heart medications on the market.

READ MORE